Join UCLA oncologist Gottfried E. Konecny, MD, for an update on the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers. Dr. Konecny will also discuss how to proactively plan for and manage treatment-related toxicities.